Cargando…

Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models

[Image: see text] The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2...

Descripción completa

Detalles Bibliográficos
Autores principales: Israel, Liron L., Galstyan, Anna, Cox, Alysia, Shatalova, Ekaterina S., Sun, Tao, Rashid, Mohammad-Harun, Grodzinski, Zachary, Chiechi, Antonella, Fuchs, Dieu-Trang, Patil, Rameshwar, Koronyo-Hamaoui, Maya, Black, Keith L., Ljubimova, Julia Y., Holler, Eggehard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413444/
https://www.ncbi.nlm.nih.gov/pubmed/35961653
http://dx.doi.org/10.1021/acsnano.1c10034
_version_ 1784775753622093824
author Israel, Liron L.
Galstyan, Anna
Cox, Alysia
Shatalova, Ekaterina S.
Sun, Tao
Rashid, Mohammad-Harun
Grodzinski, Zachary
Chiechi, Antonella
Fuchs, Dieu-Trang
Patil, Rameshwar
Koronyo-Hamaoui, Maya
Black, Keith L.
Ljubimova, Julia Y.
Holler, Eggehard
author_facet Israel, Liron L.
Galstyan, Anna
Cox, Alysia
Shatalova, Ekaterina S.
Sun, Tao
Rashid, Mohammad-Harun
Grodzinski, Zachary
Chiechi, Antonella
Fuchs, Dieu-Trang
Patil, Rameshwar
Koronyo-Hamaoui, Maya
Black, Keith L.
Ljubimova, Julia Y.
Holler, Eggehard
author_sort Israel, Liron L.
collection PubMed
description [Image: see text] The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2 (AP2), B6, Miniap-4 (M4), and d-configurated peptides D1, D3, and ACI-89, with specificity for transcytosis receptors low-density lipoprotein receptor-related protein-1 (LRP-1), transferrin receptor (TfR), bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex, respectively. The BBB-permeation efficacies were substantially increased (“boosted”) in vector conjugates of P/LLL(40%). We have found that the copolymer group binds at the endothelial membrane and, by an allosterically membrane rearrangement, exposes the sites for vector–receptor complex formation. The specificity of vectors is indicated by competition experiments with nonconjugated vectors. P/LLL(40%) does not function as an inhibitor, suggesting that the copolymer binding site is eliminated after binding of the vector-nanoconjugate. The two-step mechanism, binding to endothelial membrane and allosteric exposure of transcytosis receptors, is supposed to be an integral feature of nanoconjugate-transcytosis pathways. In vivo brain delivery signatures of the nanoconjugates were recapitulated in mouse brains of normal, tumor (glioblastoma), and Alzheimer’s disease (AD) models. BBB permeation of the tumor was most efficient, followed by normal and then AD-like brain. In tumor-bearing and normal brains, AP2 was the top performing vector; however, in AD models, D3 and D1 peptides were superior ones. The TfR vector B6 was equally efficient in normal and AD-model brains. Cross-permeation efficacies are manifested through modulated vector coligation and dosage escalation such as supra-linear dose dependence and crossover transcytosis activities.
format Online
Article
Text
id pubmed-9413444
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-94134442022-08-27 Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models Israel, Liron L. Galstyan, Anna Cox, Alysia Shatalova, Ekaterina S. Sun, Tao Rashid, Mohammad-Harun Grodzinski, Zachary Chiechi, Antonella Fuchs, Dieu-Trang Patil, Rameshwar Koronyo-Hamaoui, Maya Black, Keith L. Ljubimova, Julia Y. Holler, Eggehard ACS Nano [Image: see text] The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2 (AP2), B6, Miniap-4 (M4), and d-configurated peptides D1, D3, and ACI-89, with specificity for transcytosis receptors low-density lipoprotein receptor-related protein-1 (LRP-1), transferrin receptor (TfR), bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex, respectively. The BBB-permeation efficacies were substantially increased (“boosted”) in vector conjugates of P/LLL(40%). We have found that the copolymer group binds at the endothelial membrane and, by an allosterically membrane rearrangement, exposes the sites for vector–receptor complex formation. The specificity of vectors is indicated by competition experiments with nonconjugated vectors. P/LLL(40%) does not function as an inhibitor, suggesting that the copolymer binding site is eliminated after binding of the vector-nanoconjugate. The two-step mechanism, binding to endothelial membrane and allosteric exposure of transcytosis receptors, is supposed to be an integral feature of nanoconjugate-transcytosis pathways. In vivo brain delivery signatures of the nanoconjugates were recapitulated in mouse brains of normal, tumor (glioblastoma), and Alzheimer’s disease (AD) models. BBB permeation of the tumor was most efficient, followed by normal and then AD-like brain. In tumor-bearing and normal brains, AP2 was the top performing vector; however, in AD models, D3 and D1 peptides were superior ones. The TfR vector B6 was equally efficient in normal and AD-model brains. Cross-permeation efficacies are manifested through modulated vector coligation and dosage escalation such as supra-linear dose dependence and crossover transcytosis activities. American Chemical Society 2022-08-12 2022-08-23 /pmc/articles/PMC9413444/ /pubmed/35961653 http://dx.doi.org/10.1021/acsnano.1c10034 Text en © 2022 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Israel, Liron L.
Galstyan, Anna
Cox, Alysia
Shatalova, Ekaterina S.
Sun, Tao
Rashid, Mohammad-Harun
Grodzinski, Zachary
Chiechi, Antonella
Fuchs, Dieu-Trang
Patil, Rameshwar
Koronyo-Hamaoui, Maya
Black, Keith L.
Ljubimova, Julia Y.
Holler, Eggehard
Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
title Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
title_full Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
title_fullStr Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
title_full_unstemmed Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
title_short Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer’s, and Tumor Mouse Models
title_sort signature effects of vector-guided systemic nano bioconjugate delivery across blood-brain barrier of normal, alzheimer’s, and tumor mouse models
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413444/
https://www.ncbi.nlm.nih.gov/pubmed/35961653
http://dx.doi.org/10.1021/acsnano.1c10034
work_keys_str_mv AT israellironl signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT galstyananna signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT coxalysia signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT shatalovaekaterinas signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT suntao signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT rashidmohammadharun signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT grodzinskizachary signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT chiechiantonella signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT fuchsdieutrang signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT patilrameshwar signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT koronyohamaouimaya signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT blackkeithl signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT ljubimovajuliay signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels
AT hollereggehard signatureeffectsofvectorguidedsystemicnanobioconjugatedeliveryacrossbloodbrainbarrierofnormalalzheimersandtumormousemodels